Volume : 11, Issue : 03, March – 2024
Title:
DRUG REPURPOSING: A REVIEW
Authors :
K. Shanthamma , B.Aruna,
Abstract :
Drug repurposing (DR) also known as drug repositioning. It is a process of identifying new therapeutic use for old/existing/available drugs. Drug repositioning utilises the combined efforts of activity- based or experimental and in silico-based or computational approaches to develop/identify the new uses of drug molecules on a rational basis. This systemic analysis can help in computational methods implemented on biological resources. It is necessary to discover new strategies for reducing the drug discovery time frame strategies to discover new indications for FDA approved drug are are discussed in this article.Drug discovery involves de- novo identification and of new molecular entities(NME). The drug discovery by this approach is certainly advantageous. for example sildenafil (Viagra),a phosphodiesterase-5(PDE5)inhibitory initially developed for coronary artery disease(angina)by Pfizer(1985) has been repurposed for the treatment of erectile dysfunction.
Keywords: Drug repurposing, drug discovery, insilico repositioning, activity- based repositioning, target-based screening, therapeutic indication.
Cite This Article:
Please cite this article in press B.Aruna et al., Drug Repurposing: A Review., Indo Am. J. P. Sci, 2024; 11 (03).
Number of Downloads : 10
References:
1. Martorana, A.; Perricone, U.; Lauria, A. The Repurposing of Old Drugs or Unsuccessful Lead Compounds by in Silico Approaches: New Advances and Perspectives. Curr. Top. Med. Chem. 2016, 16,
2. Pushpakom, S.; Iorio, F.; Eyers, P.A.; Escott, K.J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams, T.; Latimer, J.; McNamee, C.; et al. Drug repurposing: Progress, challenges and recommendations. Nat. Rev. Drug Discov. 2019, 18, 41–58.
3. Gouveia, M.J.; Brindley, P.J.; Gärtner, F.; da Costa, J.M.C.; Vale, N. Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules. Pharmaceuticals 2018, 11, 15
4. Lv, B.-M.; Tong, X.-Y.; Quan, Y.; Liu, M.-Y.; Zhang, Q.; Song, Y.; Zhang, H.-Y. Drug Repurposing for Japanese Encephalitis Virus Infection by Systems Biology Methods. Molecules 2018, 23, 3346.
5. Seliger, C.; Hau, P. Drug Repurposing of Metabolic Agents in Malignant Glioma. Int. J. Mol. Sci. 2018, 19, 2768. J. Clin. Med. 2020, 9, 3777 11 of 14
6. Cha, Y.; Erez, T.; Reynolds, I.J.; Kumar, D.; Ross, J.; Koytiger, G.; Kusko, R.; Zeskind, B.; Risso, S.; Kagan, E.; et al. Drug repurposing from the perspective of pharmaceutical companies. Br. J. Pharmacol. 2017, 175, 168–180.
7. Giovannoni, G.; Baker, D.; Schmierer, K. The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? Mult. Scler. Relat. Disord. 2015, 4, 3–5.
8. Fischl, M.A.; Richman, D.D.; Grieco, M.H.; Gottlieb, M.S.; Volberding, P.A.; Laskin, O.L.; Leedom, J.M.; Groopman, J.E.; Mildvan, D.; Schooley, R.T.; et al. The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex. N. Engl. J. Med. 1987, 317, 185–191.
9. Topical minoxidil approved by FDA. Clin. Pharm. 1988, 7, 858–862
10. Goldstein, I.; Lue, T.F.; Padma-Nathan, H.; Rosen, R.C.; Steers, W.D.; Wicker, P.A. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl. J. Med. 1998, 338, 1397–1404.
11. Calabrese, L.; Resztak, K. Thalidomide revisited: Pharmacology and clinical applications. Expert Opin. Investig. Drugs 1998, 7, 2043–2060.
12. Glasmacher, A.; Hahn, C.; Hoffmann, F.; Naumann, R.; Goldschmidt, H.; Lilienfeld-Toal, M.; Orlopp, K.; Schmidt-Wolf, I.; Gorschlüter, M. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 2006, 132, 584–593.
13. Steinbach, G.; Lynch, P.M.; Phillips, R.K.; Wallace, M.H.; Hawk, E.; Gordon, G.B.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; et al. The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis. New Engl. J. Med. 2000, 342, 1946–1952.
14. Michelson, D.; Allen, A.J.; Busner, J.; Casat, C.; Dunn, D.; Kratochvil, C.; Newcorn, J.; Sallee, F.R.; Sangal, R.B.; Saylor, K.; et al. Once-Daily Atomoxetine Treatment for Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study. Am. J. Psychiatry 2002, 159, 1896–1901.
15. Emery, P.; Fleischmann, R.; Filipowicz-Sosnowska, A.; Schechtman, J.; Szczepanski, L.; Kavanaugh, A.; Racewicz, A.J.; van Vollenhoven, R.F.; Li, N.F.; Agarwal, S.; et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006, 54, 1390– 1400.
16. Fabian, C.J. Tamoxifen or raloxifene in postmenopausal women for prevention of breast cancer: A tale of two choices-counterpoint. Cancer Epidemiol. Biomar. Prev. 2007, 16, 2210–2212.
17. Chun, J.; Hartung, H.-P. Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis. Clin. Neuropharmacol. 2010, 33, 91–101.
18. McMahon, C.G. Dapoxetine: A new option in the medical management of premature ejaculation. Ther. Adv. Urol. 2012, 4, 233–251.
19. Garvey, W.T.; Ryan, D.H.; Look, M.; Gadde, K.M.; Allison, D.B.; Peterson, C.A.; Schwiers, M.; Day, W.W.; Bowden, C.H. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study. Am. J. Clin. Nutr. 2012, 95, 297–308.
20. Castinetti, F.; Guignat, L.; Giraud, P.; Muller, M.; Kamenicky, P.; Drui, D.; Bihan, H. Ketoconazole in Cushing’s disease: Is it worth a try? J. Clin. Endocrinol. Metab. 2014, 99, 1623–1630.
21. Drew, D.A.; Cao, Y.; Chan, A.T. Aspirin and colorectal cancer: The promise of precision chemoprevention. Nat. Rev. Cancer 2016, 16, 173–186.
22. Pammolli, F.; Magazzini, L.; Riccaboni, M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 2011, 10, 428–438 23. Scannell, J.W.; Blanckley, A.; Boldon, H.; Warrington, B. Diagnosing the decline in pharmaceutical